抗体探索サービスとプラットフォーム市場（第5版）：提供するサービスのタイプ別分布（抗原設計、ヒット生成、リード選択、リード最適化、リード特性評価）、抗体探索手法（ハイブリドーマベース、ライブラリーベース、シングルセルベース、トランスジェニック動物ベース）、生成される抗体のタイプ（モノクローナル抗体、二重特異性抗体、その他）、生成される抗体の性質（キメラ、ヒト、ヒト化、マウス）、治療領域の種類（心血管疾患、免疫学的疾患、感染症疾患、神経学的疾患、腫瘍学的疾患、その他）、主要地域（北米、欧州、アジア、中南米、中東・北アフリカ、その他の地域）：産業動向と世界予測、2023-2035年

Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

世界の抗体探索サービス・プラットフォーム市場は、2023年までに16億米ドルに達すると予測され、予測期間2023-2035年の年平均成長率は12%と予測されている。創薬から市場投入までの医薬品開発には、通常10～1... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Roots Analysis ルーツアナリシス	2023年9月23日	US$4,799 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	525	英語

サマリー

世界の抗体探索サービス・プラットフォーム市場は、2023年までに16億米ドルに達すると予測され、予測期間2023-2035年の年平均成長率は12%と予測されている。

創薬から市場投入までの医薬品開発には、通常10～15年の歳月がかかり、20億ドルを超える多額の投資が必要とされる。残念なことに、医薬品候補の90％以上は臨床試験に合格しない。このプロセスを合理化し、タイムラインを短縮し、リスクを管理するために、製薬会社は創薬業務の一部を専門の開発業務受託機関（CRO）にアウトソーシングしている。抗体CROとのコラボレーションは、抗体創薬市場の企業にとって、リソースの最適化、コスト削減、グローバルな科学的人材の活用に役立ち、抗体ベースの新治療法の市場投入における効率と成功率を高めます。

1986年に承認されたOrthoclone OKT3®のようなモノクローナル抗体ベースの治療法は、大きく進歩しました。モノクローナル抗体は、多様化し、工学的に改良され、革新的な探索方法の恩恵を受けている。がん、慢性炎症性疾患、感染症、心血管系疾患など様々な疾患に対して160以上のモノクローナル抗体が承認されている。最近では、ELREXFIO™、TALVEY™、Rystiggo®、COLUMVI®、EPKINLY™などの治療薬が2023年5月から2023年8月の間に承認された。こうした抗体の探索は複雑であるため、多くの企業が抗体探索に特化したプラットフォームや技術のライセンス供与を選択している。抗体ベースの治療に対する需要の高まりとアウトソーシングの選好は、抗体探索サービスやプラットフォームが将来的に大幅に拡大すると予想されることを示している。

レポート対象範囲
 本レポートでは、抗体探索市場を幅広く調査し、サービスタイプ、探索手法、抗体タイプ、性質、治療分野、主要地域別に分類しています。
 推進要因、阻害要因、機会、課題などの市場成長の影響要因を徹底的に分析しています。
 本レポートでは、市場ランドスケープにおける利点と障害の両方を評価し、トップ市場プレイヤー間の競争環境に関する洞察を提供しています。
 主要6地域にわたる市場セグメントの収益予測を提供しています。
 体系的な調査手法、方法論、前提条件、採用した品質管理対策に関する詳細な洞察により、調査結果の正確性と信頼性を保証しています。
 分析には、抗体探索サービスやプラットフォームに影響を与える過去のトレンド、為替変動、為替の影響、景気後退の影響、インフレ測定などが含まれています。
 市場の現状を簡潔に概観し、抗体探索サービスおよびプラットフォーム市場の短期、中期、長期の進化を予測します。
 モノクローナル型、二重特異性型、ポリクローナル型を中心に、抗体の歴史的背景、構造詳細、アイソタイプ、作用機序、用途を包括的に網羅。
 過去30年間におけるマウスからヒトへのモノクローナル抗体の発展傾向を追跡し、発見方法の詳細な検討と比較を行う。
 設立年、企業規模、所在地、提供サービス、探索方法、使用動物モデル、抗体の種類、目的など様々なパラメータに基づき、160を超える活動中のサービスプロバイダーを分析。
 経験、プラットフォーム、提供サービス、探索手法、抗体フォーマット、応用分野、地域能力に基づく企業の比較評価。
 抗体探索サービスを提供する企業の会社概要、最近の動向、将来の展望を含む詳細なプロフィール。
 抗体の種類、探索方法、動物モデル、設立年、企業規模、本社所在地に基づく290以上のプラットフォームの検討。
 サプライヤーの力、プラットフォームの仕様、抗体の互換性、2015-2023年に締結された取引を考慮した主要市場プレイヤーの評価。
 企業概要、プラットフォームの詳細、最近の開発状況、将来の展望など、抗体探索プラットフォームや技術へのアクセス/ライセンスを提供する企業の詳細情報。
 2021年から2023年にかけて抗体探索市場内で確立されたパートナーシップの評価、ステークホルダーが採用したパートナーシップモデルの説明。
 2016年から2023年にかけての抗体探索市場における様々な資金調達段階と資金源にわたる投資の調査。
 キャッシュフロー、正味現在価値、ライセンサーとライセンシー間の契約一時金、マイルストーン、ロイヤルティ支払いのシナリオに関する洞察。
 抗体ヒト化サービスにおける業界特有の動向、市場促進要因、課題、主要企業、影響因子に関する詳細な考察。
 2022年の売上上位医薬品について、過去の売上、探索プロセス、手法など詳細なプロフィールを紹介。
 今後10年間に業界の進化に影響を与えると予想される、今後の抗体治療薬や技術に関する考察。

主要市場企業
 Ablexis
 Antibody Solutions
 ケムパートナー
 Creative Biolabs
 GenScript
 Genmab
 ハーバーバイオメド
 ImmunoPrecise
 マブシリコ
 Myrio Therapeutics
 ノナ・バイオサイエンシズ
 ロックランド免疫化学
 シンバイオテクノロジー
 WuXi Biologics

ページTOPに戻る

1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation
2.7. Key Market Segmentation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Classification of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Polyclonal Antibodies
5.6.3. Bispecific Antibodies
5.7. Applications of Antibodies
5.8. Concluding Remarks
6. ANTIBODY DISCOVERY: PROCESS AND METHODS
6.1. Chapter Overview
6.2. Antibody Discovery Process
6.2.1. Target Selection and Validation
6.2.2. Hit Generation
6.2.3. Lead Selection
6.2.4. Lead Optimization
6.2.4.1. Humanization
6.2.4.2. Affinity Maturation
6.2.4.3. Fc Engineering
6.2.5. Lead Characterization
6.2.6. Candidate Selection
6.3. Antibody Discovery Methods
6.3.1. Hybridoma Technology-based Method
6.3.2. In vitro Display Method
6.3.2.1. Phage Display
6.3.2.2. Yeast Display
6.3.2.3. Ribosomal Display
6.3.3. Transgenic Animal-based Method
6.3.4. Single B Cell-based Method
6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
6.4. Evolution of Monoclonal Antibodies
6.4.1. Fully Human Monoclonal Antibodies
6.5. Concluding Remarks
7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Antibody Discovery Services Offered
7.2.5. Analysis by Type of Antibody Discovered
7.2.6. Analysis by Type of Antibody Discovery Method
7.2.7. Analysis by Animal Model Used
7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
7.2.10. Analysis by Application Area
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped Grouped based on Company Size
8.4.1. Very Small Companies Offering Antibody Discovery Services
8.4.2. Small Companies Offering Antibody Discovery Services
8.4.3. Mid-sized Companies Offering Antibody Discovery Services
8.4.4. Large Companies Offering Antibody Discovery Services
8.5. Antibody Discovery Service Providers: Regional Capability
8.5.1. Antibody Discovery Service Providers based in North America
8.5.2. Antibody Discovery Service Providers based in Europe
8.5.3. Antibody Discovery Service Providers based in Asia
9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
9.2.1. Abwiz Bio
9.2.1.1. Company Overview
9.2.1.2. Recent Developments and Future Outlook
9.2.2. Abzena
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook
9.2.3. Aragen Life Sciences
9.2.3.1. Company Overview
9.2.3.2. Recent Developments and Future Outlook
9.2.4. Capralogics
9.2.4.1. Company Overview
9.2.4.2. Recent Developments and Future Outlook
9.2.5. Creative Biolabs
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Recent Developments and Future Outlook
9.2.6. DetaiBio
9.2.6.1. Company Overview
9.2.6.2. Recent Developments and Future Outlook
9.2.7. ImmunoPrecise Antibodies
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. Recent Developments and Future Outlook
9.2.8. Integral Molecular
9.2.8.1. Company Overview
9.2.8.2. Recent Developments and Future Outlook
9.2.9. Syd Labs
9.2.9.1. Company Overview
9.2.9.2. Recent Developments and Future Outlook
9.3. Antibody Discovery Service Providers in Europe
9.3.1. BIOTEM
9.3.1.1. Company Overview
9.3.1.2. Recent Developments and Future Outlook
9.3.2. FairJourney Biologics
9.3.2.1. Company Overview
9.3.2.2. Recent Developments and Future Outlook
9.3.3. Fusion Antibodies
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook
9.3.4. Proteogenix
9.3.4.1. Company Overview
9.3.4.2. Recent Developments and Future Outlook
9.3.5. RD Biotech
9.3.5.1. Company Overview
9.3.5.2. Recent Developments and Future Outlook
9.4. Antibody Discovery Service Providers in Asia
9.4.1. ABGENEX
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook
9.4.2. ChemPartner
9.4.2.1. Company Overview
9.4.2.2. Recent Developments and Future Outlook
9.4.3. Viva Biotech
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook
9.4.4. WuXi Biologics
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Recent Developments and Future Outlook
10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies
10.2.1. Analysis by Type of Antibody Discovery Method
10.2.2. Analysis by Type of Antibody Discovered
10.2.3. Analysis by Animal Model Used
10.2.4. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
10.2.5. Analysis by Type of Antibody Discovery Method and Location of Headquarters
10.3. Antibody Discovery Technologies: Developer Landscape
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Most Active Players: Analysis by Number of Technologies
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Antibody Discovery Technologies: Competitiveness Analysis
11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World
12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
12.1. Chapter Overview
12.2. Ablexis
12.2.1. Company Overview
12.2.2. Antibody Discovery Platform Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. Creative Biolabs
12.3.1. Company Overview
12.3.2. Antibody Discovery Platform Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Genmab
12.4.1. Company Overview
12.4.2. Financial Information
12.4.3. Antibody Discovery Platform Portfolio
12.4.4. Recent Developments and Future Outlook
12.5. Harbour Biomed
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Antibody Discovery Platform Portfolio
12.5.4. Recent Developments and Future Outlook
12.6. Immunome
12.6.1. Company Overview
12.6.2. Antibody Discovery Platform Portfolio
12.6.3. Recent Developments and Future Outlook
12.7. Isogenica
12.7.1. Company Overview
12.7.2. Antibody Discovery Platform Portfolio
12.7.3. Recent Developments and Future Outlook
12.8. Ligand Pharmaceuticals
12.8.1. Company Overview
12.8.2. Financial Information
12.8.3. Antibody Discovery Platform Portfolio
12.8.4. Recent Developments and Future Outlook
12.9. Kymab
12.9.1. Company Overview
12.9.2. Antibody Discovery Platform Portfolio
12.9.3. Recent Developments and Future Outlook
12.10. MorphoSys
12.10.1. Company Overview
12.10.2. Financial Information
12.10.3. Antibody Discovery Platform Portfolio
12.10.4. Recent Developments and Future Outlook
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year of Partnership and Type of Partner
13.3.4. Analysis by Type of Antibody
13.3.5. Most Active Players: Analysis by Number of Partnerships
13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.8. Intracontinental and Intercontinental Agreements
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Type of Funding
14.3.3. Analysis of Amount Invested by Year of Funding
14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested
14.3.7. Leading Investors: Analysis by Number of Funding Instances
14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
14.3.9. Analysis by Year-wise Amount Invested and Type of Player
14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
14.3.11. Analysis by Geography
14.4. Concluding Remarks
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
16.3.1. Scenario Analysis
16.4. Key Market Segmentations
16..5. Dynamic Dashboard
17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology

17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation and Validation
18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.9. Data Triangulation and Validation
19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation
20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.9. Data Triangulation and Validation
21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.9. Data Triangulation and Validation
22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis
22.4. Key Market Segmentations
22.5. Dynamic Dashboard
23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation and Validation
24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.6. Data Triangulation and Validation
25. LICENSING DEAL STRUCTURE
25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
25.3.1. Overall Cash Flow for Licensee Companies
25.3.1.1. Investments Made by a Licensee
25.3.1.2. Revenues Earned by a Licensee

25.3.2. Overall Cash Flow for Licensor Companies
25.3.2.1. Investments Made by a Licensor
25.3.2.2. Revenues Earned by a Licensor
25.4. Key Analytical Outputs
25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties
26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
26.3.1. Strengths
26.3.2. Weaknesses
26.3.3. Opportunities
26.3.4. Threats
27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
27.1. Chapter Overview
27.2. Humira® (Adalimumab)
27.2.1. Drug Overview
27.2.2. Discovery Process and Method
27.2.3. Historical Sales
27.3. Keytruda® (Pembrolizumab)
27.3.1. Drug Overview
27.3.2. Discovery Process and Method
27.3.3. Historical Sales
27.4. Stelara® (Ustekinumab)
27.4.1. Drug Overview
27.4.2. Discovery Process and Method
27.4.3. Historical Sales
27.5. Dupixent® (Dupilumab)
27.5.1. Drug Overview
27.5.2. Discovery Process and Method
27.5.3. Historical Sales
27.6. Opdivo® (Nivolumab)
27.6.1. Drug Overview
27.6.2. Discovery Process and Method
27.6.3. Historical Sales
28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks
29. CONCLUSION
30. EXECUTIVE INSIGHTS
30.1. Chapter Overview
30.2. Antibody Solutions
30.2.1. Company Snapshot
30.2.2. Interview Transcript
30.3. Adimab
30.3.1. Company Snapshot
30.3.3. Interview Transcript
30.4. ImmunoPrecise Antibodies
30.4.1. Company Snapshot
30.4.3. Interview Transcript
30.5. Anonymous
30.5.1. Anonymous, Chief Business Officer (Q3 2023)
30.6. Abveris, Acquired by Twist Biosciences
30.6.1. Company Snapshot
30.6.2. Interview Transcript
30.7. Nidus BioSciences
30.7.1. Company Snapshot
30.7.2. Interview Transcript
30.8. AvantGen
30.8.1. Company Snapshot
30.8.2. Interview Transcript
30.9. Single Cell Technology
30.9.1. Company Snapshot
30.9.2. Interview Transcript
30.10. Distributed Bio
30.10.1. Company Snapshot
30.10.2. Interview Transcript
30.11. AbCellera
30.11.1. Company Snapshot
30.11.2. Interview Transcript
30.12. AbGenics Life Sciences
30.12.1. Company Snapshot
30.12.2. Interview Transcript
30.13. CDI Laboratories
30.13.1. Company Snapshot
30.13.2. Interview Transcript
30.14. AP Biosciences
30.14.1. Company Snapshot
30.14.2. Interview Transcript
30.15. YUMAB
30.15.1. Company Snapshot
30.15.2. Interview Transcript
30.16. Antibody Solutions
30.16.1. Company Snapshot
30.16.2. Interview Transcript
30.17. Ligand Pharmaceuticals
30.17.1. Company Snapshot
30.17.2. Interview Transcript
30.18. LakePharma
30.18.1. Company Snapshot
30.18.2. Interview Transcript
31. APPENDIX 1: TABULATED DATA
32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

ページTOPに戻る

Table of Contents

Summary

The global antibody discovery services and platforms market is expected to reach USD 1.6 billion by 2023 anticipated to grow at a CAGR of 12% during the forecast period 2023-2035.

Developing drugs, from discovery to market, usually spans 10-15 years and involves substantial investments, often exceeding $2 billion. Unfortunately, more than 90% of drug candidates don't pass clinical trials. To streamline this process, reduce timelines, and manage the risk, pharmaceutical companies are outsourcing aspects of their discovery work to specialized contract research organizations (CROs). Collaborating with antibody CROs helps companies in the antibody discovery market optimize resources, cut costs, and tap into a global scientific talent pool, enhancing efficiency and success rates in bringing new antibody-based therapies to market.

Monoclonal antibody-based therapies, like Orthoclone OKT3® approved in 1986, have advanced significantly. They've diversified in formats, undergone engineering improvements, and benefited from innovative discovery methods. Over 160 monoclonal antibodies have been approved for various diseases, including cancer, chronic inflammatory conditions, infectious diseases, and cardiovascular ailments. Recently, therapies like ELREXFIO™, TALVEY™, Rystiggo®, COLUMVI®, and EPKINLY™ were approved between May 2023 and August 2023. Due to the complexity of discovering these antibodies, many companies choose to license specialized antibody discovery platforms and technologies. The growing demand for antibody-based therapies and the preference for outsourcing indicate a significant expected expansion in antibody discovery services and platforms in the future.

Report Coverage
 The report extensively examines the antibody discovery market, categorizing it by service type, discovery method, antibody type, nature, therapeutic fields, and key geographical regions.
 It thoroughly analyzes market growth influencers such as drivers, restraints, opportunities, and challenges.
 The report evaluates both advantages and obstacles within the market landscape and offers insights into the competitive environment among top market players.
 Revenue forecasts for market segments are provided across six major regions.
 Detailed insights into the systematic research approach, methodologies, assumptions, and quality control measures employed ensure the accuracy and reliability of findings.
 Analysis encompasses historical trends, currency fluctuations, foreign exchange impacts, recession effects, and inflation measurements affecting antibody discovery services and platforms.
 It provides a concise overview of the present market status and forecasts the short, mid, and long-term evolution of the antibody discovery services and platforms market.
 Comprehensive coverage of historical context, structural details, isotypes, mechanisms of action, and applications of antibodies, with emphasis on monoclonal, bispecific, and polyclonal types.
 Detailed examination and comparison of discovery methods, tracking the developmental trends of monoclonal antibodies from murine to human variants over the past three decades.
 Analysis of over 160 active service providers based on various parameters such as establishment year, company size, location, services offered, discovery methods, animal models used, types of antibodies, and purposes.
 Comparative evaluation of companies based on experience, platforms, services offered, discovery methods, antibody formats, application areas, and regional capabilities.
 In-depth profiles of companies providing antibody discovery services, including company overview, recent developments, and future outlook.
 Examination of 290+ platforms based on antibody types, discovery methods, animal models, establishment year, company size, and headquarters location.
 Assessment of leading market players considering supplier power, platform specifications, antibody compatibility, and deals signed between 2015-2023.
 Detailed information about companies offering access/licenses to their antibody discovery platforms or technologies, including company overview, platform details, recent developments, and future outlook.
 Evaluation of partnerships established within the antibody discovery market from 2021-2023, with descriptions of partnership models adopted by stakeholders.
 Examination of investments in the antibody discovery market from 2016-2023 across various financing stages and sources.
 Insights into cash flows, net present values, and scenarios of upfront, milestone, and royalty payments between licensors and licensees.
 Detailed discussion on industry-specific trends, market drivers, challenges, key players, and influencing factors in antibody humanization services.
 Presentation of detailed profiles of top-selling drugs in 2022, including historical sales, discovery processes, and methods.
 Discussion on upcoming antibody therapeutics and technologies expected to impact the industry's evolution in the coming decade.

Key Market Companies
 Ablexis
 Antibody Solutions
 ChemPartner
 Creative Biolabs
 GenScript
 Genmab
 Harbour BioMed
 ImmunoPrecise
 MabSilico
 Myrio Therapeutics
 Nona Biosciences
 Rockland Immunochemicals
 Synbio technologies
 WuXi Biologics

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Roots Analysis 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

Roots Analysisは2013年設立の医薬品・医療機器が専門の調査会社です。医薬品の製造委託や創薬のデジタル化など、最新の医薬業界の分析を行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Roots Analysis 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?